
        <!DOCTYPE html>
        <html>
        <head>
            <title>ULTRAGENYX PHARMACEUTICAL INC. (RARE) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">ULTRAGENYX PHARMACEUTICAL INC. (RARE)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">21</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">9</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">8</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.05</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=cce8e26af7e0bbf726d89b4877966dd1befb023a0e80ab11263c10a9af0751bf" target="_blank" rel="noopener noreferrer">Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.38
                                </span>
                            </div>
                            <div class="article-summary">Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, a key study of an Ultragenyx and Mereo drug is continuing past a second interim analysis....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8c42b092d9fb62a54cecd7fc6d70c479b251f878510595923e75e5757ecd48aa" target="_blank" rel="noopener noreferrer">US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.35
                                </span>
                            </div>
                            <div class="article-summary">The U.S. Food and DrugAdministration has declined to approve UltragenyxPharmaceutical's experimental gene therapy to treat arare genetic disorder, the company said on Friday.(Reporting by Kamal......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d600f9c16d14c45ad47deac1c2f226b60aaf328d27b5d6e8d1470447e956d5a1" target="_blank" rel="noopener noreferrer">US FDA declines to approve Ultragenyx's gene therapy for rare inherited disorder</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.92
                                </span>
                            </div>
                            <div class="article-summary">The U.S. Food and DrugAdministration has declined to approve UltragenyxPharmaceutical's experimental gene therapy to treat arare inherited disorder, citing manufacturing concerns, thecompany said......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2091796384a567f4ef6c167be0971002881fb943cbc546ef5a1a4d3f92228c09" target="_blank" rel="noopener noreferrer">Ultragenyx Says Metabolic Disorder Treatment Approval Likely Delayed to 2026</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-11</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.55
                                </span>
                            </div>
                            <div class="article-summary">By Dean Seal Ultragenyx Pharmaceutical said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3033ed803fdd6acfbbbbd6d88e1140ebc2d16f10dd3735ca77be440dd8c46a71" target="_blank" rel="noopener noreferrer">Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.82
                                </span>
                            </div>
                            <div class="article-summary">Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable FDA clinical reviews acknowledged that the clinical data are robust a...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c5fe045667dfeb4e42031da517c3bbd2ccd2f7a138375a694723f2230430374c" target="_blank" rel="noopener noreferrer">Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.85
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b640b0c62563bf95b22a9e2f2a577e735767724f20aa33db11b95baa12a75417" target="_blank" rel="noopener noreferrer">Sector Update: Health Care Stocks Mixed Premarket Thursday</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Health care stocks were mixed premarket Thursday as the Health Care Select Sector SPDR Fund (XLV) wa...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=658649ae1e5c80b79ee3097273c1e2da706ad2cde8ac86134630ecea07af97a2" target="_blank" rel="noopener noreferrer">Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=48ffe3f7f3a2761afad8236324e1f67cc13a01bdecbf54bda7765a0022c27de8" target="_blank" rel="noopener noreferrer">RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.96
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=aa39aba081af80f9f00d8551b68f85d1f5c8f636d0a3d46c5720f91cb8fb09a6" target="_blank" rel="noopener noreferrer">Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.58
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx and Mereo stocks crashed Thursday after their treatment for brittle bone disease missed its mark in a second interim look....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1b54e36ea0460fc0153af2493bea468caeb6dfb23c3baa9bf69d6ba8bbd62108" target="_blank" rel="noopener noreferrer">Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    -0.00
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to end it early....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8506aa8882a9e59c10949f83f0a30a1972009b024d6c52829388c7dcc41054f1" target="_blank" rel="noopener noreferrer">Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.34
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2bd31cb4234a9fc9396e3834061ddbde79fc0d65626a1ddd33a2db82afea3325" target="_blank" rel="noopener noreferrer">Top Midday Decliners</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical (RARE) shares dropped 26% after a phase 3 study update of UX143 missed a k...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f3e27a63147a30bb0a66741eddf37645fb4195c7ebc4b6f3a658f9c6070851a1" target="_blank" rel="noopener noreferrer">Sector Update: Health Care Stocks Rise Late Afternoon</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.9% and...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c8ea5d804d736e938791b2e97feb792c15e9fa888d2881a943d2cdad656e0d4a" target="_blank" rel="noopener noreferrer">Ultragenyx’s GTX-102 Receives FDA Breakthrough Therapy Designation for Angelman Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-09</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.69
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks according to Wall Street analysts. On June 27, Ultragenyx Pharmaceutical announced that the US FDA granted Breakthrough...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=41374fb7da95be035775925e5633f0c68509272b840fcec6f64e9c63718a9594" target="_blank" rel="noopener noreferrer">Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-09</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.30
                                </span>
                            </div>
                            <div class="article-summary">Data from Orbit and Cosmic studies expected around the end of the yearNOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NAS...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=36ee1af2d5f3c0bedf9d827928e9698214181abd38fa39ea9ccc037d0808014c" target="_blank" rel="noopener noreferrer">High Growth Tech Stocks In The US Market With Promising Potential</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.91
                                </span>
                            </div>
                            <div class="article-summary">The U.S. stock market has recently experienced a surge, with the S&P 500 and Nasdaq Composite reaching new all-time highs following a robust June jobs report that exceeded expectations and fueled opti...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2380a33098a6f80b874c78bc06f5c5c3b692854656888cf5da8a9e11c87edc60" target="_blank" rel="noopener noreferrer">Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.93
                                </span>
                            </div>
                            <div class="article-summary">NOVATO - Ultragenyx Pharmaceutical Inc. , announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for GTX-102 as a treatment for Angelman......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ff67a93becaa91eb2f78bc6df403e2039d4fd6bcedf232f9ba7d9103b863d312" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-27</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.92
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for GTX-102 as a treatment for Angelman syndrome. The FDA's......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7cd505e269d9596199601bbc55e98f4c3e35dc14eb2508d7328b3dc694834dba" target="_blank" rel="noopener noreferrer">Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=888e169590425d0b04646e475e4a44c603e3ef61b4a9462821aeb378d6af90db" target="_blank" rel="noopener noreferrer">Tracking Baker Brothers Portfolio - Q1 2025 Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-17</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Baker Brothersâ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and high-conviction strategies....</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        